ADDEX THERAPEUTICS LTD Geneva, Switzerland, January 12, 2021 - https://www.globenewswire.com/Tracker?data=CIhmp7x-qIz7EYiMHtqR3anKfF_WtTWb7VGiA_xyqvgJmXPW65tv8LeudhbJBkgH0B_KVTXdVjqfMi14q9_OeYKz3dO35ION5imqAto1fFA= Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that Tim Dyer, Chief Executive Officer, is scheduled to participate in the virtual https://www.globenewswire.com/Tracker?data=9WbZwBf3700Kbk09g01W86D8V-w4LfGtDpdx-ziYOLRbgjNofm65QzZV_eKRFq9ys-KVUqAVCYIEgG7sHvLPmLf4ginmNPlpmSgnjjYOtGMs2kaFzohBg1qBo2Y9v86L_16QbBSScGrMT9XusRez-g== Baader Helvea Swiss Equities Conference taking place on January 13 -- January 15, 2021. In the presentation, which will take place on January 13, 2021 at 14:50 - 15:30 CET, Mr Dyer will provide a corporate update and discuss recent developments. He will be available for virtual one-on-one meetings throughout the conference. About Addex Therapeutics: https://www.globenewswire.com/Tracker?data=CIhmp7x-qIz7EYiMHtqR3cQ5SdKFyAg0uwglnRigLZv-SHF19CiI4InZeOIYG8djWDIdtZpHsz-5Iz78PIusU_jPd3BMrxZmUmRyEBnK-5hPd4rnFhFHoesVJFjGOTnI Addex Therapeutics is a clinical-stage pharmaceutical company focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators for neurological disorders. Allosteric modulators offer several potential advantages over conventional non-allosteric molecules and may offer an improved therapeutic approach to conventional "orthosteric" small molecule or biological drugs. Addex's allosteric modulator drug discovery platform targets receptors and other proteins that are recognized as essential for therapeutic intervention. Addex's lead drug candidate, dipraglurant (mGlu5 negative allosteric modulator or NAM), is poised to start a pivotal registration clinical trial for Parkinson's disease levodopa induced dyskinesia (PD-LID) in H1 2021. Addex is also investigating dipraglurant's therapeutic use in blepharospasm (a type of dystonia), for which a clinical trial is expected to be initiated in H1 2021. Addex's third clinical program, ADX71149 (mGlu2 positive allosteric modulator or PAM), developed in collaboration with Janssen Pharmaceuticals, Inc., is scheduled to enter a phase 2a proof of concept clinical study for the treatment of epilepsy in H1 2021. Addex's GABAB PAM program has been licensed to Indivior PLC for the treatment of addiction. Preclinical programs include GABA(B) PAM for CMT1A, mGlu7 NAM for PTSD, mGlu2 NAM for mild neurocognitive disorders, mGlu4 PAM for Parkinson's disease and mGlu3 PAM for neurodegenerative disorders. Addex is listed on the SIX Swiss Exchange and NASDAQ Capital Market, and trades under the ticker symbol "ADXN". Press Contacts: Tim Dyer Mike Sinclair Chief Executive Officer Partner, Halsin Partners Telephone: +41 22 884 15 55 +44 (0)20 7318 2955 Email: mailto:PR@addextherapeutics.com PR@addextherapeutics.com mailto:msinclair@halsin.com msinclair@halsin.com ---------------------------------------------------------------- ------------------------------------------------- Forward Looking Statements: This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including in respect of the anticipated initiation of clinical trials. The words "may," "will," "could," "would," "should," "expect," "plan," "anticipate," "intend," "believe," "estimate," "predict," "project," "potential," "continue," "target" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in Addex Therapeutics' Annual Report on Form 20-F for the year ended December 31, 2019, as filed with the SEC on April 27, 2020, the prospectus related to the global offering and other filings that Addex Therapeutics may make with the SEC in the future. Any forward-looking statements contained in this press release represent Addex Therapeutics' views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Addex Therapeutics explicitly disclaims any obligation to update any forward-looking statements.
(END) Dow Jones Newswires
January 12, 2021 01:00 ET (06:00 GMT)
